IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 1)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here.
1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05)
2. Which patient subgroups are most likely to respond to this therapeutic approach? (1:40)
3. What are the major challenges in the manufacturing of CAR-T cells? (3:28)
Ibrahim El Houssieny has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Immunotherapy
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer
Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy
touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!